Daiichi Sankyo Provides Update on FDA Review of Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML

TOKYO and BASKING RIDGE, N.J., June 21, 2019 -- (Healthcare Sales & Marketing Network) -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the company received a Complete Response Letter (CRL) from the U.S. Food and Drug Ad... Biopharmaceuticals, Oncology, FDA Daiichi Sankyo, quizartinib, acute myeloid leukemia, FLT3 inhibitor
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news